Psilocybin-Research.com
Research. Clarity. Progress.
Executed search
Journal: PsyArXiv
216 matching records are displayed.
Clear search Latest Publications
Most recently published records currently stored in SQLite.
1-20
Last updated: Jul 3, 2026 01:22 UTC
Checking for newly published papers…
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
ClinicalTrials.gov · 2026-07-01
Meskalin / Mescaline
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
DMT und Ayahuasca / DMT and Ayahuasca
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
DMT und Ayahuasca / DMT and Ayahuasca
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia
Revista CienciaUANL · 2026-06-30
Meskalin / Mescaline
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
Usos recreativos, medicinales y etnobotánicos de hongos alucinógenos: una revisión
Multidisciplinary Collaborative Journal · 2026-06-30
Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms
Journal of Drug Issues · 2026-06-30
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
ClinicalTrials.gov · 2026-06-30
Psilocybin shows mixed results for patients with treatment-resistant depression
The Brown University Psychopharmacology Update · 2026-06-30
Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessation
The Brown University Psychopharmacology Update · 2026-06-30
Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review
Journal of Affective Disorders Reports · 2026-06-30
Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.
Palliative medicine · 2026-06-30
Record check: Jul 3, 2026 01:22 UTC
Daily cron-ready
216matching papers
3,834psilocybin
553psilocin
388journals
3,975all time
Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355
The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The study, HIC: 200020355 (Neural correlates of the effects of psilocybin in obsessive-compulsive disorder: A double-blind, ...
Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355
The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The study, HIC: 200020355 (Neural correlates of the effects of psilocybin in obsessive-compulsive disorder: A double-blind, ...
Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing
Background: Therapeutic administration of psychedelic drugs has shown significant potential in historical accounts and in recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilo...
Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing
Background: Therapeutic administration of psychedelic drugs has shown significant potential in historical accounts and in recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilo...
From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)
Background: The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs, and offers a unified account of the acute and therapeutic action of psychedelics. Although REBUS has received some neuroscientific support, little research has examined its psychologic...
From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)
Background: The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs, and offers a unified account of the acute and therapeutic action of psychedelics. Although REBUS has received some neuroscientific support, little research has examined its psychologic...
A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression
Objectives: To perform a Bayesian reanalysis of a recent trial of psilocybin (COMP360) versus escitalopram for Major Depressive Disorder (MDD) in order to provide a more informative interpretation of the indeterminate outcome of a previous frequentist analysis. Design: Reanalysis of a two-arm double-blind placebo controlled trial.Participants: Fifty-nine pat...
A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression
Objectives: To perform a Bayesian reanalysis of a recent trial of psilocybin (COMP360) versus escitalopram for Major Depressive Disorder (MDD) in order to provide a more informative interpretation of the indeterminate outcome of a previous frequentist analysis. Design: Reanalysis of a two-arm double-blind placebo controlled trial. Participants: Fifty-nine pa...
Neuroimaging in psychedelic drug development: Past, present, and future
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating a range of psychiatric disorders, including depression, addiction, eating disorders, post-traumatic stress disorder, and others. ‘Classic’ serotonergic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), N, N-Dimethyltryptamine (DMT) and 5-metho...
Neuroimaging in psychedelic drug development: Past, present, and future
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating a range of psychiatric disorders, including depression, addiction, eating disorders, post-traumatic stress disorder, and others. ‘Classic’ serotonergic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), N, N-Dimethyltryptamine (DMT) and 5-metho...
A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
This document details an authors' response to a critique of their work entitled: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds.
A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
This document details an authors' response to a critique of their work entitled: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds.
Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
Here we raise issues in Daws et al. (2022) published in Nature Medicine.
Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
Here we raise issues in Daws et al. (2022) published in Nature Medicine.
Predictors of Psychedelic Experience: A Thematic Analysis
Research on the therapeutic potential of psychedelic substances is rapidly expanding. A major limitation within this field is the unpredictability of individual responses to psychedelic substances. A better understanding of factors that can predict psychedelic experience is essential to both clinical progress and wider harm reduction frameworks. Ketamine, MD...
Predictors of Psychedelic Experience: A Thematic Analysis
Research on the therapeutic potential of psychedelic substances is rapidly expanding. A major limitation within this field is the unpredictability of individual responses to psychedelic substances. A better understanding of factors that can predict psychedelic experience is essential to both clinical progress and wider harm reduction frameworks. Ketamine, MD...
A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects
Psychedelic drugs such as psilocybin are under investigation for the treatment of several psychiatric conditions. They also have the remarkable property of producing persisting positive psychological changes in healthy volunteers for at least several months. In this study, 35 medium-high doses of psilocybin were administered to 28 healthy volunteers (12 fema...
A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects
Psychedelic drugs such as psilocybin are under investigation for the treatment of several psychiatric conditions. They also have the remarkable property of producing persisting positive psychological changes in healthy volunteers for at least several months. In this study, 35 medium-high doses of psilocybin were administered to 28 healthy volunteers (12 fema...
Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test
Background: Due to increasing evidence of efficacy in treating mental health disorders, psilocybin may become a legal medicinal drug. This study tested the validity of Carhart-Harris & Nutt (2017) model of extra-pharmacological (EP) factors and examined whether such factors should be taken into account in any psychological suitability test for medicinally pr...
Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test
Background: Due to increasing evidence of efficacy in treating mental health disorders, psilocybin may become a legal medicinal drug. This study tested the validity of Carhart-Harris & Nutt (2017) model of extra-pharmacological (EP) factors and examined whether such factors should be taken into account in any psychological suitability test for medicinally pr...